Aridis Pharmaceuticals (ARDS) Stock Price
Aridis Pharmaceuticals Price
Revenue has compounded at 31.3% per year over the past 7 years to 19.25 M USD. Aridis Pharmaceuticals's net margin stands at -159.7%, up from -801.8% several years earlier.
Aridis Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Aridis Pharmaceuticals business model & stock analysis
Frequently asked questions about Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative anti-infective therapies. The company focuses on utilizing its proprietary technology platforms to create monoclonal antibodies that can effectively target and neutralize infectious pathogens. By harnessing the power of the immune system, Aridis Pharmaceuticals aims to provide solutions for combating a wide range of infectious diseases, including bacterial, fungal, and viral infections. Through strategic partnerships and collaborations, the company aims to accelerate the development and commercialization of its product candidates, bringing much-needed therapeutic options to patients worldwide.
Aridis Pharmaceuticals Inc primarily operates in the biotechnology and pharmaceutical industries.
The main competitors of Aridis Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc, Moderna Inc, GlaxoSmithKline plc, and AstraZeneca plc.
Aridis Pharmaceuticals Inc, founded in 2003, is a biopharmaceutical company based in San Jose, California. Specializing in the discovery and development of targeted immunotherapies to treat infectious diseases, Aridis Pharmaceuticals has made significant advancements in combating severe infections. The company has a robust pipeline of novel therapies, utilizing its proprietary technologies such as Monoclonal Antibody AR-301, designed to neutralize bacterial toxins associated with severe pneumonia. Aridis Pharmaceuticals focuses on improving patient outcomes and reducing healthcare costs through the development of highly effective and safe immunotherapies. With a commitment to innovation, Aridis Pharmaceuticals is at the forefront of addressing unmet medical needs in the field of infectious diseases.
Aridis Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully completed a Phase 1 clinical trial for its lead candidate, AR-301, a potential treatment for severe pneumonia caused by bacterial infections. Aridis also entered into a licensing agreement with Bharat Biotech to develop a vaccine for COVID-19. Furthermore, the company received a grant from the National Institutes of Health to support the development of AR-201, a potential treatment for hospital-acquired pneumonia. These achievements demonstrate Aridis Pharmaceuticals Inc's commitment to advancing innovative therapies for infectious diseases and its potential to make a significant impact in the healthcare industry.
Aridis Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of innovative anti-infective therapies. With its headquarters in San Jose, California, the company leverages its proprietary technologies to address global infectious diseases. Aridis Pharmaceuticals Inc's presence extends beyond regional bounds, as it collaborates with international partners, conducts clinical trials, and explores potential expansion opportunities. Expanding its reach and impact, Aridis Pharmaceuticals Inc remains committed to delivering breakthrough treatments worldwide, combating infectious diseases and improving patient outcomes.
Aridis Pharmaceuticals Inc represents values of innovation, dedication, and commitment to improving global health. The company's corporate philosophy revolves around developing targeted and effective immunotherapies for infectious diseases. Aridis Pharmaceuticals Inc is focused on pioneering the development of novel monoclonal antibodies and antiviral therapeutics to combat various pathogens. With a strong emphasis on research and development, Aridis strives to bring groundbreaking treatments to market, addressing critical unmet medical needs. By leveraging advanced technologies and strategic collaborations, Aridis Pharmaceuticals Inc aims to make a positive impact on society by providing life-saving solutions for infectious diseases.
7 analysts currently rate the Aridis Pharmaceuticals stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Aridis Pharmaceuticals share trades at 0.00 EUR (0.00 USD).
The Aridis Pharmaceuticals share (ARDS) is listed on 1 stock exchanges, including: NASDAQ (ARDS).
Aridis Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company's business model is based on several areas, including research and development, production, and distribution. Aridis focuses on the discovery and development of novel immunotherapies, particularly monoclonal antibodies and immunomodulators that specifically target the underlying pathomechanisms of infectious diseases. The company has an extensive pipeline of product candidates targeting various bacterial and viral infections. Aridis also places importance on quality and efficient processes in its production facilities. The company collaborates closely with leading pharmaceutical companies and distribution partners for international marketing and distribution. In addition to infectious diseases, Aridis aims to expand its technology and expertise in immunology to other areas such as cancer immunotherapies and autoimmune diseases. The company works with academic institutions and government agencies to enhance its research efforts and accelerate the development of novel immunotherapies. Overall, Aridis' business model is based on the development and commercialization of innovative immunotherapies for infectious diseases, with a strong focus on research and development, efficient production, and collaborations with partners.
The revenue cannot currently be calculated for Aridis Pharmaceuticals.
The profit cannot currently be calculated for Aridis Pharmaceuticals.
The P/E ratio cannot be calculated for Aridis Pharmaceuticals at the moment.
The P/S cannot be calculated for Aridis Pharmaceuticals currently.
The Eulerpool Quality Score for Aridis Pharmaceuticals is 5/10.
The ISIN of Aridis Pharmaceuticals is US0403341045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Aridis Pharmaceuticals is A2N38H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Aridis Pharmaceuticals is ARDS. The ticker symbol is used to trade Aridis Pharmaceuticals shares on the stock exchange.
Aridis Pharmaceuticals stock
Aridis Pharmaceuticals Peer Group
Aridis Pharmaceuticals Ticker
Aridis Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Aridis Pharmaceuticals
Our stock analysis for Aridis Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aridis Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.